ASCO® 2026 Highlights: Presenter Vignette – Marlana Orloff

Dr. Marlana Orloff

Marlana Orloff

MD

Thomas Jefferson University Hospital

LBA9503

Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.